Year: 2023
Type: article
Abstract: Procalcitonin is a biomarker that often is elevated in response to a bacterial infection, whereas viral infections suppress procalcitonin production through interferon-γ.1 The PRORATA trial supported its usefulness in antibiotic stewardship by encouraging antibiotic use for procalcitonin levels of ≥ 0.5 ng/mL and discontinuation of < 0.25 ng/mL in critically ill patients.2 Procalcitonin can be elevated in COVID-19 because of bacterial coinfection, inflammation, or excessive cytokine production. Studies suggest that procalcitonin level may predict disease severity in COVID-19, but it may not indicate a bacterial infection reliably in this population.
Source: CHEST Critical Care
Authors: Shahin Isha, Parthkumar Satashia, Lekhya Raavi, Sadhana Jonna, Anna Jenkins, Abby J. Hanson, Emily C. Craver, Arvind Balavenkataraman, Aysun Tekin, Vikas Bansal, Sean M. Caples, Syed Anjum Khan, Nitesh K. Jain, Abigail T. LaNou, Rahul Kashyap, Rodrigo Cartin-Ceba, Bhavesh M. Patel, Ricardo Diaz Milian, Carla P. Venegas, Anna B. Shapiro, Anirban Bhattacharyya, Sanjay Chaudhary, Sean P. Kiley, Young M. Erben, Quintin J. Quinones, Neal M. Patel, Pramod K. Guru, Pablo Moreno Franco, Devang K. Sanghavi, Archana Roy
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,500
OpenAlex ID: W4389306008